IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Sanford Health
Leap Therapeutics, Inc.
Revolution Medicines, Inc.
University of Oxford
Cairo University
Advaxis, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Fate Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
AbbVie
Karyopharm Therapeutics Inc
H. Lee Moffitt Cancer Center and Research Institute
University of Zurich
MacroGenics
Ottawa Hospital Research Institute
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Takara Bio Inc.
Centre Hospitalier Universitaire de Nīmes
Inovio Pharmaceuticals
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
The University of Texas Medical Branch, Galveston
Traws Pharma, Inc.
Sanofi
University Health Network, Toronto
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center
Blaze Bioscience Australia Pty Ltd
Icahn School of Medicine at Mount Sinai
PCI Biotech AS
University Hospital, Ghent
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
National Baromedical Services
Stanford University
Pharmacyclics LLC.
National Institutes of Health Clinical Center (CC)